Abstract: Baloxavir marboxil is a new anti-influenza drug developed by Shionogi in Japan. It was launched in Japan in February 2018 for the treatment of influenza caused by influenza A and B viruses. Compared with other anti-influenza drugs, baloxavir marboxil has a unique anti-viral mechanism, requiring only one oral dose at a time, with fewer side effects and good patient compliance. In this review, the mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials, and so on of this medicine were discussed.